Bellicum Pharmaceuticals Inc.

2.95-0.0400-1.34%Vol 67.35K1Y Perf -57.98%
Jul 23rd, 2021 16:00 DELAYED
BID2.95 ASK2.96
Open2.99 Previous Close2.99
Pre-Market- After-Market-
 - -  - -%
Target Price
4.50 
Analyst Rating
Strong Buy 1.00
Potential %
52.54 
Finscreener Ranking
★★★ —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
+     36.68
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     47.77
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap24.77M 
Earnings Rating
Neutral
Price Range Ratio 52W %
6.76 
Earnings Date
5th Aug 2021

Today's Price Range

2.933.00

52W Range

2.578.19

5 Year PE Ratio Range

-3.90-1.20

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.68%
1 Month
-15.23%
3 Months
-6.65%
6 Months
-29.26%
1 Year
-57.98%
3 Years
-95.67%
5 Years
-97.87%
10 Years
-

TickerPriceChg.Chg.%
BLCM2.95-0.0400-1.34
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Financial StrengthValueIndustryS&P 500US Markets
1.10
1.20
0.97
36.23
-20.80
Leverage Ratio -4.70
ProfitabilityValueIndustryS&P 500US Markets
-
-6 977.40
-6 711.00
-15 865.60
-
RevenueValueIndustryS&P 500US Markets
500.00K
0.06
-2.05
37.14
Earnings HistoryEstimateReportedSurprise %
Q01 2021--0.89-
Q04 2020--3.05-
Q03 2020-3.29-2.5821.58
Q02 2020--2.47-
Q01 2020-1.09-
Q04 2019-4.90-2.9440.00
Q03 2019-5.70-5.80-1.75
Q02 2019-5.40-5.80-7.41
Earnings Per EndEstimateRevision %Trend
12/2020 QR-1.0568.75Positive
12/2020 QR-3.3674.15Positive
12/2021 FY-3.39-11.51Negative
12/2022 FY-1.81--
Next Report Date5th Aug 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume67.35K
Shares Outstanding8.40M
Trades Count452
Dollar Volume1.19M
Avg. Volume420.53K
Avg. Weekly Volume68.25K
Avg. Monthly Volume91.31K
Avg. Quarterly Volume142.76K

Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM) stock closed at 2.95 per share at the end of the most recent trading day (a -1.34% change compared to the prior day closing price) with a volume of 67.35K shares and market capitalization of 24.77M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 107 people. Bellicum Pharmaceuticals Inc. CEO is Richard A. Fair.

The one-year performance of Bellicum Pharmaceuticals Inc. stock is -57.98%, while year-to-date (YTD) performance is -16.43%. BLCM stock has a five-year performance of -97.87%. Its 52-week range is between 2.57 and 8.19, which gives BLCM stock a 52-week price range ratio of 6.76%

Bellicum Pharmaceuticals Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 36.97, a price-to-sale (PS) ratio of 48.37, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.95%, a ROC of -130.15% and a ROE of 244.42%. The company’s profit margin is -%, its EBITDA margin is -6 711.00%, and its revenue ttm is $500.00 Thousand , which makes it $0.06 revenue per share.

Of the last four earnings reports from Bellicum Pharmaceuticals Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Bellicum Pharmaceuticals Inc.’s next earnings report date is 05th Aug 2021.

The consensus rating of Wall Street analysts for Bellicum Pharmaceuticals Inc. is Strong Buy (1), with a target price of $4.5, which is +52.54% compared to the current price. The earnings rating for Bellicum Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bellicum Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bellicum Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.61, ATR14 : 0.21, CCI20 : -101.30, Chaikin Money Flow : -0.04, MACD : -0.07, Money Flow Index : 36.66, ROC : -8.39, RSI : 43.93, STOCH (14,3) : 16.85, STOCH RSI : 0.39, UO : 43.59, Williams %R : -83.15), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bellicum Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
1 (33.33 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.33

Bellicum Pharmaceuticals Inc.

Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy (Rivo-cel) to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology (BPX-601) to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and BCMA GoCAR-NK the program targeting B-cell maturation antigen.

CEO: Richard A. Fair

Telephone: +1 832 384-1100

Address: 2130 West Holcombe Boulevard, Houston 77030, TX, US

Number of employees: 107

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

57%43%

Bearish Bullish

59%41%

News

Stocktwits